NASDAQ
CLVS

Clovis Oncology Inc

Biotechnology & Medical Research
Healthcare

Prices are adjusted according to historical splits.

Clovis Oncology Inc Stock Price

Vitals

Today's Low:
$0.075
Today's High:
$0.098
Open Price:
$0.075
52W Low:
$0.0422
52W High:
$3.25
Prev. Close:
$0.09
Volume:
361782

Company Statistics

Market Cap.:
$11.77 million
Book Value:
-2.886
Revenue TTM:
$133.02 million
Operating Margin TTM:
-155.16%
Gross Profit TTM:
$115.30 million
Profit Margin:
-189.38%
Return on Assets TTM:
-30.18%
Return on Equity TTM:
0%

Company Profile

Clovis Oncology Inc had its IPO on 2011-11-16 under the ticker symbol CLVS.

The company operates in the Healthcare sector and Biotechnology & Medical Research industry. Clovis Oncology Inc has a staff strength of 413 employees.

Stock update

Shares of Clovis Oncology Inc opened at $0.08 at the start of the last trading session i.e. 2023-03-19.

The stocks traded within a range of $0.08 - $0.1, and closed at $0.09.

This is a +3.33% increase from the previous day's closing price.

A total volume of 361,782 shares were traded at the close of the day’s session.

In the last one week, shares of Clovis Oncology Inc have slipped by -6.06%.

Clovis Oncology Inc's Key Ratios

Clovis Oncology Inc has a market cap of $11.77 million, indicating a price to book ratio of 0 and a price to sales ratio of 0.107.

In the last 12-months Clovis Oncology Inc’s revenue was $133.02 million with a gross profit of $115.30 million and an EBITDA of $-198676000. The EBITDA ratio measures Clovis Oncology Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Clovis Oncology Inc’s operating margin was -155.16% while its return on assets stood at -30.18% with a return of equity of 0%.

In Q3, Clovis Oncology Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 19.1%.

Clovis Oncology Inc’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG
0.13

Its diluted EPS in the last 12-months stands at $-2.084 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0.13. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Clovis Oncology Inc’s profitability.

Clovis Oncology Inc stock is trading at a EV to sales ratio of 4.8964 and a EV to EBITDA ratio of -3.1061. Its price to sales ratio in the trailing 12-months stood at 0.107.

Clovis Oncology Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$346.78 million
Total Liabilities
$747.87 million
Operating Cash Flow
$-89000.00
Capital Expenditure
$89000
Dividend Payout Ratio
0%

Clovis Oncology Inc ended 2023 with $346.78 million in total assets and $0 in total liabilities. Its intangible assets were valued at $346.78 million while shareholder equity stood at $-417886000.00.

Clovis Oncology Inc ended 2023 with $0 in deferred long-term liabilities, $747.87 million in other current liabilities, 145000.00 in common stock, $-3064766000.00 in retained earnings and $63.07 million in goodwill. Its cash balance stood at $58.32 million and cash and short-term investments were $58.32 million. The company’s total short-term debt was $3,454,000 while long-term debt stood at $0.

Clovis Oncology Inc’s total current assets stands at $102.21 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $19.45 million compared to accounts payable of $18.12 million and inventory worth $11.42 million.

In 2023, Clovis Oncology Inc's operating cash flow was $-89000.00 while its capital expenditure stood at $89000.

Comparatively, Clovis Oncology Inc paid $0 in dividends in 2023.

Other key metrics

Current Trading Price
$0.09
52-Week High
$3.25
52-Week Low
$0.0422
Analyst Target Price
$2

Clovis Oncology Inc stock is currently trading at $0.09 per share. It touched a 52-week high of $3.25 and a 52-week low of $3.25. Analysts tracking the stock have a 12-month average target price of $2.

Its 50-day moving average was $0.1 and 200-day moving average was $0.89 The short ratio stood at 4.63 indicating a short percent outstanding of 0%.

Around 143.8% of the company’s stock are held by insiders while 2589.8% are held by institutions.

Frequently Asked Questions About Clovis Oncology Inc

The stock symbol (also called stock or share ticker) of Clovis Oncology Inc is CLVS

The IPO of Clovis Oncology Inc took place on 2011-11-16

Similar Industry Stocks (Biotechnology & Medical Research)

Last Price
Chg
Chg%
$12.74
0.07
+0.55%
$7.01
-0.45
-6.03%
$15.04
-1.45
-8.79%
$0.95
0
0%
$13.1
-0.44
-3.25%
$0.03
-0
-10.71%
$3.51
0.27
+8.33%
$0.4
0.01
+2.56%
$0.11
0
+1.37%

Most Active

Last Price
Chg
Chg%
$0.14
-0.01
-6.67%
$2.48
-0.01
-0.4%
$11.3
-0.52
-4.4%
$1813.35
106.75
+6.26%
$0.05
-0
-2.13%

Top Gainers

Last Price
Chg
Chg%
$0
0
+58723.53%
$0
0
+20460.42%
$0.63
0
+2548.22%
$0.02
0
+1566.67%

Top Losers

Last Price
Chg
Chg%
NGC-WT (NGC-WT)
$0
-0.04
-94.66%
$0
-0.01
-91.67%
PICCW (PICCW)
$0.01
-0.05
-90%
$4.7
-33.3
-87.63%

About

Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as well as for metastatic castration-resistant prostate cancer. In Europe, the company offers Rubraca for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. It is also developing lucitanib, an investigational angiogenesis inhibitor, which inhibits vascular endothelial growth factor receptors 1 through 3 (VEGFR 1-3), platelet-derived growth factor receptors alpha and beta (PDGFRa/ß), and fibroblast growth factor receptors 1 through 3 (FGFR 1-3);and FAP-2286, an investigational peptide-targeted radionuclide therapy and imaging agent targeting fibroblast activation protein. In addition, the company sells its Rubraca through a limited number of specialty distributor and specialty pharmacy providers, who subsequently sells Rubraca to patients and health care providers. Clovis Oncology, Inc. has license agreements with Pfizer Inc., AstraZeneca UK Limited, Advenchen Laboratories LLC, and 3B Pharmaceuticals GmbH, a clinical collaboration with Bristol Myers Squibb Company; and a partnership with Foundation Medicine, Inc. Clovis Oncology, Inc. was incorporated in 2009 and is headquartered in Boulder, Colorado. On December 11, 2022, Clovis Oncology, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Address

5500 Flatiron Parkway, Boulder, CO, United States, 80301